共 308 条
[1]
Haque R(2017)Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study Br J Cancer 117 1233-1240
[2]
UlcickasYood M(2006)Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24 4448-4456
[3]
Xu X(1940)Quantitative studies of prostatic secretion : ii. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs J Exp Med 72 747-762
[4]
Cassidy-Bushrow AE(2018)Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol Off J Am Soc Clin Oncol 36 1521-1539
[5]
Tsai HT(2002)A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer J Urol 167 1670-1674
[6]
Keating NL(2000)Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 566-577
[7]
van den Eeden SK(2012)Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study The Lancet Oncology 13 983-992
[8]
Potosky AL(2017)Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer N Engl J Med 377 352-360
[9]
Keating NL(2012)LHRH agonists for the treatment of prostate cancer: 2012 Reviews in urology 14 1-12
[10]
O’Malley AJ(2017)Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study Eur Urol 72 920-928